AstraZeneca Posts Positive Trial Results
AstraZeneca's ALXN1850 shows favourable safety profile and meets key secondary endpoint in bone health in Mulberry Phase III trial
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.